PRODUCTRARE DISEASE ASSETS

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is a rare disease company focused on developing and commercializing transformational therapies for patients with limited or no treatment options. The company maintains a diverse portfolio of commercial assets and product candidates, including OLPRUVA® (sodium phenylbutyrate) an FDA approved treatment for urea cycle disorders, MIPLYFFATM (arimoclomol) (now FDA approved) for Niemann-Pick disease type C, KP1077 in development for idiopathic hypersomnia, and celiprolol in development for vascular Ehlers-Danlos syndrome. Additionally, the company receives royalties and milestones on AZSTARYS® (serdexmethylphenidate and dexmethylphenidate), which is marketed by Corium, LLC for the treatment of attention deficit and hyperactivity disorder.

Background

As Zevra Therapeutics continues to execute upon its strategic goal of becoming a leading rare disease company, the company was seeking additional non-dilutive capital. Through a credit facility of up to $100 million provided HealthCare Royalty and Perceptive Advisors, the company refinanced and streamlined its existing debt. This move also secured additional funds to extend its cash runway, support the OLPRUVA® launch, prepare for the launch of MIPLYFFA, and advance its pipeline development.